Last reviewed · How we verify

NCT06146582

The Impact of a Personalized Care Intervention on 90-day Post-Discharge Care

Completed NA Last updated 20 March 2024
What this trial tests

NA trial testing Laguna Coach and App Intervention Group in Cardiovascular Diseases in 187 participants. Completed in 29 December 2023.

Timeline
15 November 2021
Primary endpoint
5 October 2023
29 December 2023

Quick facts

Lead sponsorLaguna Health, Inc
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment187
Start date15 November 2021
Primary completion5 October 2023
Estimated completion29 December 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Laguna Health, Inc

Who can join

18 and older, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this 90 day study is to demonstrate the extent to which participants with cardiovascular conditions can improve their recovery at home through a mobile app, support and resources made available to them after hospitalization. The study will evaluate the effectiveness of personal care intervention support, including one-on-one guidance, educational information, check-ins, and Laguna's mobile app to help participants recover better after hospitalization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Laguna Health, Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06146582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing